- Report
- May 2024
- 200 Pages
Global
From €3722EUR$4,150USD£3,217GBP
- Report
- January 2024
- 200 Pages
Global
From €3722EUR$4,150USD£3,217GBP
- Report
- March 2024
- 117 Pages
Global
From €4036EUR$4,500USD£3,489GBP
- Report
- August 2022
- 119 Pages
Global
From €4036EUR$4,500USD£3,489GBP
- Report
- December 2024
- 200 Pages
Global
From €2242EUR$2,500USD£1,938GBP
- Report
- April 2025
- 186 Pages
Global
From €4036EUR$4,500USD£3,489GBP
- Report
- July 2023
- 118 Pages
Global
From €4036EUR$4,500USD£3,489GBP
- Report
- February 2025
Global
From €4440EUR$4,950USD£3,837GBP
- Report
- September 2025
- 70 Pages
India
From €3139EUR$3,500USD£2,713GBP
- Report
- June 2024
- 132 Pages
North America
From €3588EUR$4,000USD£3,101GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1345EUR$1,500USD£1,163GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1345EUR$1,500USD£1,163GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1121EUR$1,250USD£969GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1121EUR$1,250USD£969GBP
- Clinical Trials
- April 2025
- 120 Pages
Global
From €1794EUR$2,000USD£1,550GBP
- Report
- July 2024
- 150 Pages
Global
From €3364EUR$3,750USD£2,907GBP
- Report
- July 2024
- 100 Pages
Global
From €3364EUR$3,750USD£2,907GBP
- Report
- September 2025
- 70 Pages
India
From €3139EUR$3,500USD£2,713GBP
- Report
- September 2025
- 70 Pages
India
From €3139EUR$3,500USD£2,713GBP
- Report
- September 2025
- 88 Pages
India
From €3139EUR$3,500USD£2,713GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more